NSCLC患者血清VEGF及VEGFR-2化疗前后的变化及临床意义

Clinical significance of the serum levels of VEGF and VEGFR-2 in patients with non-small cell lung cancer before and after chemotherapy

目的:探讨NSCLC患者化疗前后血清中VEGF和VEGFR-2的变化、两者相关性及临床意义。方法:用ELISA法检测45例NSCLC患者(化疗组)化疗前后血清中VEGF及VEGFR-2的表达水平,并与20例健康人(对照组)作比较。结果:化疗组化疗前血清VEGF、VEGFR-2表达水平与健康对照组比较明显升高(P<0.01)。3个周期化疗后,部分缓解组VEGF、VEGFR-2表达水平均较化疗前明显降低(P<0.05),降低程度高于稳定组(P<0.05);稳定组化疗后VEGF、VEGFR-2水平较化疗前显著降低(P<0.05);进展组化疗后VEGF、VEGFR-2水平均较部分缓解组和稳定组化疗后显著升高(P<0.05)。化疗前VEGF水平与VEGFR-2表达呈正相关(P<0.05)。结论:NSCLC患者血清中VEGF、VEGFR-2均高表达。测定NSCLC患者化疗前后血清VEGF、VEGFR-2水平的变化有助于临床判断化疗效果及肿瘤进程。

Objective： To approch the clinical significance of the serum level changes of vascular endothelial growth factor（VEGF） and vascular endothelial growth factor receptor 2 （ VEGFR - 2 ） in patients with non - small cell lung cancer before and after chemotherapy, and explore the relationship between VEGF and VEGFR - 2 expression in non - small cell lung cancer. Methods ：The serum levels of VEGF and VEGFR - 2 of 45 cases with non - small cell lung cancer were detected by ELISA and compared with 20 healthy people. Results：The serum levels of VEGF and VEGFR- 2 in non- small cell lung cancer patients before chemotherapy were significantly higher than those in the healthy people（ P 〈0.01 ）. The serum levels in partial remission patients in three - weeks after chemotherapy were significantly lower than pre - chemotherapy（ P 〈 0.05 ）. The VEGF, VEGFR - 2 levels in the stable patients were al- so lower than before chemotherapy（P 〈0.05）. The serum levels in the progression group were markedly higher than after treatment（ P 〈 0.05）. There was positive correlation in serum levels of VEGF and VEGFR - 2 before chemother- apy （P 〈 0.05 ）. Conclusion：The serum levels of VEGF and VEGFR -2 in non -small cell lung cancer are high ex- pression. The determination of VEGF and VEGFR - 2 in patients with non - small cell lung cancer before and after chemotherapy is helpful to determine the effect of chemotherapy and the progression of tumor.